During the last session, Relay Therapeutics Inc. (NASDAQ:RLAY)’s traded shares were 0.45 million. At the end of the trading day, the stock’s price was $31.40, reflecting an intraday loss of -0.66% or -$0.21. The 52-week high for the RLAY share is $64.37, that puts it down -105.0 from that peak though still a striking 18.09% gain since the share price plummeted to a 52-week low of $25.72. The company’s market capitalization is $3.45B, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 852.69K shares over the past three months.
Relay Therapeutics Inc. (RLAY) registered a -0.66% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.66% in intraday trading to $31.40 this Wednesday, 11/24/21, hitting a weekly high. The stock’s 5-day price performance is -12.63%, and it has moved by 0.83% in 30 days. Based on these gigs, the overall price performance for the year is -41.85%. The short interest in Relay Therapeutics Inc. (NASDAQ:RLAY) is 8.69 million shares and it means that shorts have 15.36 day(s) to cover.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Relay Therapeutics Inc. (RLAY) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 78.70% this quarter and then drop -190.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -93.80% compared to the previous financial year.
Revenue for the current quarter is expected to be $110k as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $3.21 million by the end of Dec 2021.
While earnings are projected to return -195.40% in 2021.
Relay Therapeutics Inc. is due to release its next quarterly earnings between August 25 and August 30. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Relay Therapeutics Inc. (NASDAQ:RLAY)’s Major holders
Relay Therapeutics Inc. insiders own 4.12% of total outstanding shares while institutional holders control 92.44%, with the float percentage being 96.42%. SB Investment Advisers (UK) LTD is the largest shareholder of the company, while 209 institutions own stock in it. As of Mar 30, 2021, the company held over 27.9 million shares (or 30.21% of all shares), a total value of $964.67 million in shares.
The next largest institutional holding, with 5.83 million shares, is of FMR, LLC’s that is approximately 6.31% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $201.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Relay Therapeutics Inc. (RLAY) shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.4 million shares. This amounts to just over 1.51 percent of the company’s overall shares, with a $48.37 million market value. The same data shows that the other fund manager holds slightly less at 1.29 million, or about 1.40% of the stock, which is worth about $41.03 million.